SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Minoxidil	Finasteride	Dutasteride
Research Topic	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology
Pharmacology	Vasodilator medicine; topical and oral contexts differ	Type II 5-alpha-reductase inhibitor medicine	Dual type I and II 5-alpha-reductase inhibitor medicine
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence
Evidence boundary	Minoxidil is classified here as Vasodilator medicine; topical and oral contexts differ. Topical hair-loss and oral antihypertensive evidence cannot be interchanged without product and route boundaries. FDA-regulated topical products and prescription oral labels exist in distinct contexts; a catalogue tablet does not establish indication or authorisation. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Finasteride is classified here as Type II 5-alpha-reductase inhibitor medicine. Randomised and label evidence supports defined benign-prostatic-hyperplasia and androgenetic-alopecia products. FDA-authorised prescription products exist for defined indications; the catalogue name does not establish product approval. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Dutasteride is classified here as Dual type I and II 5-alpha-reductase inhibitor medicine. Prescription evidence supports defined benign-prostatic-hyperplasia products; hair-loss use and country approvals must be separated. FDA-authorised products exist for BPH; other indications and supplier products require jurisdiction-specific verification. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	Insufficient data in the current dataset
Limitations	Minoxidil molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Finasteride molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Dutasteride molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use
Sources	DailyMed · Minoxidil human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Finasteride human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Dutasteride human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.